As per the State Council Joint Coronavirus Prevention and Control mechanism, China approved two inactivated vaccine candidates for clinical testing for COVID-19.
The two vaccine candidates were created by the Wuhan Institute of Biological Products under the Chinese National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a corporation based in Beijing. Clinical tests of the two vaccines have begun.
Both vaccines represent China’s first set of COVID-19 inactivated vaccines to have been approved for clinical trials.
The inactivated vaccines have the advantages of mature manufacturing systems, quality controls, and a wide protective range through the use of killed pathogenic microorganisms to increase immunogenicity.
Their protection and efficacy can be verified on an globally agreed basis for large-scale vaccination.